Ionis Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of a Pending Investigation Into Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals told investors its CARDIO-TTRansform program was on track to deliver landmark data -- then the Phase-3 trial missed its primary endpoint. Levi & Korsinsky is investigating. NEW YORK, July 9, 2026 /PRNewswire/ -- Ionis Pharmaceuticals (NASDAQ: IONS) shares were...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.